Abstract
Introduction: Chondrosarcoma is the second most common malignant solid tumour of bone. The management of extra-axial low grade chondrosarcomas remains a controversial issue. Many groups advocate wide excision, necessitating substantial reconstructive surgery, often requiring massive endoprostheses or allografts. Our unit favours intralesional curettage, as it is less invasive and results in smaller defects affecting only the medulla, which can be reconstructed using simpler methods. The purpose of this study was to assess the oncological and functional outcomes of this treatment strategy.
Methods: Using our database, we identified patients with long bone chondrosarcoma that had undergone intralesional curettage between 1999 and 2001. The resultant defects had been filled with PMMA cement in 22 cases and bone graft in 2 cases. A review of all notes and radiographs was performed, with functional assessment of all available patients using the Musculoskeletal Tumour Society Scoring (MSTS).
Results: 24 consecutive cases were identified; 11 cases affecting the distal femur, 8 in the proximal humerus, 3 in the tibia and 1 each of the scapula and radius. Average age was 47 years, (range 22–75). Tumour grade was: grade 1 – 22 cases and grade 2 in 2 cases. Mean follow-up was 52 months, (range 38–73 months). There was a single case of local recurrence in a patient that had a grade 2 lesion; there were no incidences of metastases. Functional outcome was assessed in 20 of the 23 remaining cases, scoring a mean 93.7% (range 53–100) on the MSTS.
Conclusion: This study suggests intralesional curettage is an effective treatment strategy for extra-axial low grade chondrosarcoma with excellent oncological and functional results. Careful case selection, with stringent clinical and radiographic follow-up is recommended.
Correspondence should be addressed to BOOS at the Royal College of Surgeons, 35 - 43 Lincoln’s Inn Fields, London WC2A 3PN
